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After infection of swine with porcine reproductive and respiratory syndrome virus (PRRSV), there is a rapid
rise of PRRSV-specific nonneutralizing antibodies (NNA), while neutralizing antibodies (NA) are detectable
not sooner than 3 weeks later. To characterize neutralizing epitopes, we selected phages from a 12-mer phage
display library using anti-PRRSV neutralizing monoclonal antibody (MAb) ISU25-C1. In addition, phages
carrying peptides recognized by swine antibodies with high seroneutralizing titer were isolated after subtracting from the library those clones binding to swine anti-PRRSV serum with no neutralizing activity. Two
epitopes located in the ectodomain of PRRSV GP5 were identified. One of these epitopes, which we named
epitope B, was recognized both by neutralizing MAb ISU25-C1 and swine neutralizing serum (NS) but not by
swine nonneutralizing serum (NNS), indicating that it is a neutralizing epitope. Epitope B is sequential,
conserved among isolates, and not immunodominant. Antibodies directed against it are detected in serum late
after infection. In contrast, the other epitope, which we named epitope A, is hypervariable and immunodominant. Antibodies against it appear early after infection with PRRSV. This epitope is recognized by swine NNA
but is not recognized by either neutralizing MAb ISU25-C1 or swine NA, indicating that it is not involved in
PRRSV neutralization. During infection with PRRSV, epitope A may act as a decoy, eliciting most of the
antibodies directed to GP5 and delaying the induction of NA against epitope B for at least 3 weeks. These
results are relevant to the design of vaccines against PRRSV.
the infection followed by a low neutralizing antibody (NA) titer
that appears not sooner than 3 weeks after infection (16, 41).
GP5 possesses a small putative ectodomain comprising approximately the first 40 residues of the mature protein. The
ectodomain contains a variable number of N-glycosylation sites
(33), and it has been proposed that linear neutralizing epitopes
could be located in this region (28). Several murine monoclonal antibodies (MAbs) against GP5 have been elicited (28, 38).
GP4 (20) and M protein (40) can also elicit neutralizing MAbs.
However, those MAbs recognizing GP5 neutralize PRRSV
more effectively than the others (38).
Antibodies from pigs also seem to recognize neutralizing
epitopes in GP5, as suggested by the correlation between the
titers of NAs and anti-GP5 antibodies in sera from convalescent swine that was established (11). Nevertheless, nonneutralizing epitopes are also present in PRRSV GP5 (31), and,
unlike neutralizing epitopes, they are recognized during the
early p.i. period (16). Immunodominant epitopes in PRRSV
structural and nonstructural proteins have been characterized
(20, 25, 26, 31). However, to date, there has been no molecular
characterization of PRRSV neutralizing epitopes present in
GP5.
In the last few years, experimental data showing the importance of NAs in protection against PRRSV infection has accumulated. For example, a protective role of NAs present in
colostrum transferred to piglets was reported (12). Likewise,
antibodies passively transferred to pigs (final titer, 8) cleared
PRRSV viremia effectively (41). In addition, young pigs immunized with a DNA vaccine comprising the ORF 5 gene
developed PRRSV-specific NAs and protective immunity (29).

Porcine reproductive and respiratory syndrome (PRRS) is
currently accepted as the most important infectious disease of
swine (National Pork Producer Council, 1999/2000 Pork Issues
Handbook, http://www.porkscience.org/documents/other
/positionprrs.pdf), causinglate-term reproductive failure and
severe pneumonia in neonatal pigs. This disease is caused by
PRRS virus (PRRSV) (15), a member of the Arteriviridae family, order Nidoviridales (5, 6, 8). This enveloped virus contains
a 14.5-kb positive-strand RNA genome that encodes a replicase polyprotein (open reading frames [ORFs] 1a and 1b) and
six structural proteins (ORFs 2 to 7). The products of ORFs 2
to 4 are minor membrane-associated glycoproteins (GP2, GP3,
and GP4, respectively). The products of ORFs 5 to 7 are the
three major structural proteins (GP5, N, and M proteins, respectively).
Pigs are generally infected with PRRSV following exposure
of the mucosal surface of the respiratory tract to the virus.
Initial replication in macrophages from lungs and regional
lymph nodes is followed by viremia and systemic distribution of
virus to other macrophage populations (32, 35). Large amounts
of specific antibodies are first detectable in sera at around 9
days postinfection (p.i.) (18), while specific immunoglobulin G
(IgG) antibodies peak at 3 or 4 weeks after infection. A hallmark of the swine antibody response against PRRSV is the
abundant nonneutralizing antibodies (NNA) detected early in
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Finally, passively transferred NAs prevented transplacental infection and completely cleared PRRSV infection in pregnant
sows (F. A. Osorio, J. A. Galeota, E. Nelson, B. Brodersen, A.
Doster, R. Wills, F. Zuckermann, and W. W. Laegreid, submitted for publication). In all, these results clearly demonstrate
the importance of NAs for protection against PRRSV.
Current vaccines against PRRSV have several drawbacks.
Modified live vaccines protect against challenge with homologous isolates but generally have a limited effect against challenge with heterologous viruses (19, 37). Furthermore, live
PRRSV vaccines generally provide at best partial protection
against clinical disease but do not prevent infection (27). Additionally, live PRRSV vaccines can revert to virulence (3, 23).
Since the attenuated vaccines induce an immune response
resembling that induced by PRRSV natural infection, they do
not induce high levels of NAs. Nevertheless, in those cases in
which vaccines have been effective to some extent, protection
could be correlated with an anamnestic NA response after
challenge (27, 29). Killed-PRRSV vaccines, on the other hand,
have proved to be less effective in prevention of both infection
and disease (24). Thus, a better understanding of PRRSV
neutralizing epitopes may contribute to the development of a
new generation of vaccines that can elicit a protective response
against PRRSV.
Herein, we show the presence of two independent epitopes
located at the N-terminal region of GP5. One of these epitopes
is located in a region recognized both by neutralizing MAb
ISU25-C1 (40) and NAs from swine. The other epitope, which
is immunodominant, is recognized by swine NNA.
MATERIALS AND METHODS
Viruses, sera, and MAbs. (i) Virus strains and cells. PRRSV isolates PRRSV
IA strain 97-7895 (1) (GenBank accession no. AF325691), PRRSV 16244B (2)
(GenBank accession no. AF046869), NVSL (provided by National Veterinary
Services Laboratory, U.S. Department of Agriculture, Animal and Plant Inspection Service, Ames, Iowa), American prototype PRRSV strain 2332 (American
Type Culture Collection), PRRSV strain KY-35 (41), modified live vaccine virus
(MLV) RespPRRS (NOBL Labs, Ames, Iowa), and modified live vaccine virus
Prime PacPRRS (Schering Plough Animal Health, Elkorn, Nebr.) were propagated and titrated in MARC-145 cells. These cells were grown in Dulbecco’s
modified Eagle’s medium supplemented with 10% fetal calf serum. None of the
strains were propagated more than twice in MARC-145 cells after last isolation
from infected tissues (wild-type strains) or after retrieval from the commercial
vaccine vial (MLV strains).
(ii) Preparation of HI sera with high titer of NAs. Hyperimmune (HI) sera
with high titer of NAs against PRRSV were prepared by hyperimmunization of
swine. A total of 13 PRRSV-free female swine weighing 300 lb each were initially
infected by oronasal inoculation with 106 50% tissue culture infective doses
(TCID50) of the PRRSV IA strain 97-7895. At 5 weeks p.i., the animals were
superinfected with a mixture of five additional PRRSV strains, which included
16244B, 2332 (American Type Culture Collection), NVSL, RespPRRS, and
Prime PacPRRS strains. Each strain was given at a dose of 106 TCID50 through
oronasal inoculation. Four weeks later each of the animals received a dose of 105
TCID50 of PRRSV IA strain 97-7895 emulsified in 2 ml of Freund’s (complete)
adjuvant via the intramuscular route. At intervals of 1.5 months thereafter, the
animals received similar doses of PRRSV IA strain 97-7895 emulsified in 2 ml of
Freund’s (incomplete) adjuvant for a range of three to six applications. The
seroneutralizing (SN) end point titer gradually increased in each of the hyperimmunized animals. Within a period of time that ranged from 7 (including three
applications of virus plus incomplete Freund’s adjuvant) to 14 months (including
six applications of virus plus incomplete Freund’s adjuvant), all of the 13 animals
reached a final end point titer that ranged between 1:32 and 1:128, with most of
the animals exhibiting an end point SN titer of ⱖ1:64. This point was considered
to be the end of the hyperimmunization process; the animals were bled out, and
all of their sera were individually collected and used to precipitate and concentrate the antibodies by ammonium sulfate treatment.
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(iii) Standardization of the antibody stocks. The total content of swine antibodies was measured by an indirect enzyme-linked immunosorbent assay
(ELISA) specific for swine IgG (Bethyl Laboratories Inc., Montgomery, Tex.).
The end point of PRRSV-neutralizing activity attained for the resulting master
stock solution was 1:256 with strains IA 97-7895, 16244B, and 2332.
Anti-PRRSV nonneutralizing sera (NNS) were obtained at the beginning of
the hyperimmunization protocol (day 20 after first infection), when nonneutralizing activity was detected (SN titer, ⬍4) and the sample-to-positive (S/P) ratio
in ELISA (IDEXX Laboratories Inc., Westbrook, Maine) was between 0.652 and
1.432 (the cutoff value for the S/P in this ELISA is 0.4). The S/P ratio is the
difference in the optical density (OD) of the test serum between viral and control
antigens divided by the difference in the OD of the positive reference between
viral and control antigens. The concentrated antibodies had a SN titer of 1:256
against all PRRSV isolates used in the hyperimmunization and a titer of 2.232 by
ELISA (IDEXX Laboratories Inc.).
Anti-PRRSV neutralizing sera (NS) were obtained at different times throughout the immunization protocol. The S/P ratios and SN titers for each serum are
indicated in Tables 3 and 5.
PRRSV-negative serum was obtained from another group of pigs of the same
genetic background that were hyperimmunized against pseudorabies virus. These
animals were negative for anti-PRRSV antibodies as detected by seroneutralization or ELISA (see Table 3).
(iv) MAbs. ISU25-C1 is an IgG1() anti-PRRSV KY-35 isolate MAb (40)
directed against a sequential epitope on GP5, as demonstrated by the recognition
of the protein electrophoresed under denaturing conditions by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis and transferred to a polyvinylidene
difluoride membrane. It has neutralization activity against several PRRSV isolates (40), including PRRSV IA 97-7895 (this paper).
ISU19-A1 is a IgG1() anti-PRRSV KY-35 isolate nonneutralizing MAb (40)
directed against a conformational epitope on protein M of PRRSV. This MAb
was used as a negative control in the present experiments.
Affinity purification of anti PRRSV antibodies. (i) Affinity purification of
anti-PRRSV swine polyclonal antibodies. Affinity purification of antibodies was
performed in accordance with the Harlow and Lane protocol (13). Briefly, a
1.5-ml volume of NS (S/P ratio by ELISA, 1.053; SN titer, 1:64) was diluted 1:10
in 10 mM Tris, pH 7.5, and passed three times through a MARC-145 cell column
in which 30 mg of uninfected MARC-145 cell lysates were coupled to CNBractivated Sepharose (Sigma, St. Louis, Mo.). This antigenic extract was prepared
by three cycles of freezing and thawing two 75-cm2 flasks of confluent uninfected
MARC-145 cells. Nonbinding antibodies were recovered and passed three times
through a cell-associated virus column in which 30 mg of MARC-145 PRRSVinfected cells (prepared by three cycles of freezing and thawing MARC-145 cells
that had been previously infected with PRRSV for 48 h) was coupled to CNBrSepharose. After extensive washing with 10 mM Tris, pH 7.5, followed by 10 mM
Tris, pH 7.5–0.5 M NaCl, specifically bound antibodies were eluted with 100 mM
glycine, pH 2.5, and pH was adjusted with 1 M Tris, pH 8.
A further purification step was performed by passing the antibodies through a
protein A/G-Sepharose resin (Sigma). After the purification, the swine antibody
solution was highly enriched with anti-PRRSV NAs possessing an SN titer of
1:32. The absence of anti-MARC-145 cell antibodies in NAs was confirmed by
immunofluorescence (data not shown).
(ii) Affinity purification of MAb ISU25-C1. A 2-ml volume of hybridoma
culture supernatant was passed three times through a cell-associated virus column. Washing and elution steps were performed as described before. Three
fractions, containing a total of 68 g of MAb ISU25-C1, were dialyzed against
phosphate-buffered saline (PBS). The antibodies were then coupled to 50 mg of
CNBr-activated Sepharose (Sigma) in accordance with the manufacturer’s indications.
Seroneutralization. The fluorescence focus neutralization assay was performed as described previously (39). Serial dilutions of test sera were incubated
for 60 min at 37°C in the presence of 100 focus-forming units of the virus in
Dulbecco’s modified Eagle’s medium containing 5% fetal calf serum. The mixtures were added to 96-well microtitration plates containing confluent MARC145 cells which had been seeded 72 h earlier. After incubation for 24 h at 37°C
in a humidified atmosphere containing 5% CO2, the cells were fixed for 5 min
with a solution of 50% methanol and 50% acetone. After extensive washing with
PBS, the expression of N protein of PRRSV was detected with MAb SDOW17
(22), followed by incubation with fluorescein isothiocyanate-conjugated goat
anti-mouse IgG (Sigma). Neutralization titers were expressed as the reciprocal of
the highest dilution that inhibited 90% of the foci present in the control wells.
Immunoaffinity selection of phages from a 12-mer peptide library. (i) Biopanning using PRRSV affinity-purified swine antibodies. Three rounds of biopanning were carried out. Briefly, 10 l of the phage library (Ph.D.12; New England
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Biolabs, Watertown, Mass.), was incubated for 30 min at room temperature with
1 g of anti-PRRSV affinity-purified antibodies with high SN titer. To capture
the phage-antibody complexes, 50 l of bovine serum albumin-blocked protein
A/G-Sepharose was incubated for 15 min with the antibody-phage complexes.
The particles of protein A/G-Sepharose were then washed 10 times with
Tris-buffered saline (TBS) containing increasing concentrations of Tween 20 in
each panning (0.05, 0.1, and 0.5% in the first, second, and third pannings,
respectively). Finally, phages were eluted by a 10-min incubation of the Sepharose in 100 mM glycine, pH 2.5. Sepharose particles were centrifuged for 30 s,
and the eluate was transferred to another tube. The pH was adjusted with 1 M
Tris, pH 8.5.
An aliquot of the eluted phages was titrated in Escherichia coli ER2738, and
the rest of the eluate was amplified for 4.5 h in a mid-log-phase E. coli ER2738
culture. Phages were then precipitated with 3.33% polyethylene glycol (PEG)
8000–0.42 M NaCl for 16 h at 4°C and titrated.
The amplified enriched library was subjected to further cycles of selection.
After the second panning with swine antibodies with high SN titer was performed, a third cycle of selection was performed with NNS to subtract those
clones interacting with NNA. Those phages that did not bind to NNA were
selected once more with the antibodies with high SN titer to further enrich for
clones expressing peptides resembling neutralizing epitopes.
(ii) Biopanning using MAb ISU25-C1 as the ligand. Two selections with
different stringency conditions were performed with MAb ISU25-C1. In the first
(low-stringency) selection, 2 l of ISU25-C1 ascites fluid was diluted in 200 l of
10 mM Tris, pH 7.5, and incubated for 30 min with the Ph.D.12 phage library.
Then, 50 l of blocked protein G-agarose was added to the phage-antibody
mixture, and the mixture was incubated for 30 min with occasional mixing. The
resin was washed with TBS containing 0.05% Tween 20 in the first panning, TBS
containing 0.1% Tween 20 in the second panning, and TBS containing 0.5%
Tween 20 in the third panning. Phages bound to ISU25-C1 were eluted with 100
mM glycine, pH 2.5.
In the second (high-stringency) selection, 2 l of ISU25-C1 ascites fluid was
diluted in 200 l of 10 mM Tris, pH 7.5, and the mixture was incubated for 30
min with the Ph.D.12 phage library. Then, 50 l of protein G-agarose (50%
aqueous solution) was added to the phage-antibody mixture, and the mixture was
incubated for 30 min with occasional mixing. In the second panning, a CNBractivated Sepharose-coupled MAb was used. In the third panning, protein G was
used again to capture the phage-antibody complexes from solution. The resin was
thoroughly washed with 10 mM Tris, pH 7.5, in the first panning, with 10 mM
Tris, pH 7.5, containing 0.5 M NaCl in the second panning, and with 10 mM Tris,
pH 7.5, containing 0.05% Tween 20 in the third panning.
(iii) Biopanning with affinity-purifed anti-peptide S2 antibodies. Anti-peptide
S2 antibodies were affinity purified from anti-PRRSV pooled precipitated antibodies. Two micrograms of these antibodies was used for each round of selection. Three pannings with protein A/G capture were performed. For the first one,
PBS with 0.1% Tween 20 was used for the binding and washing steps. For the
second and third pannings, PBS with 0.5% Tween 20 was used.
Phage cloning and sequencing. Nonamplified eluates were plated on LuriaBertani (LB) top agar containing 50 g of IPTG (isopropyl-␤-D-thiogalactopyranoside)/ml and 40 g of X-Gal (5-bromo-4-chloro-3-indolyl--D-galactopyranoside), and, after 16 h of incubation, single phage plaques were amplified in 1
ml of mid-log-phase E. coli ER2537 in LB medium for 4.5 h at 37°C.
After one precipitation with PEG 8000 as described above, DNA from the
phages was extracted and sequenced with a ⫺96 gIII sequencing primer (CCC
TCA TAG TTA GCG TAA CG) (New England Biolabs). Sequencing was
performed manually by the dideoxy-mediated chain termination method (34)
using T7 Sequenase, version 2.0, DNA polymerase (Amersham Life Sciences,
Inc.) and ␣-35S-dATP. Samples were run in gels containing 50% urea and 6%
polyacrylamide. Gels were dried onto a 3MM paper and exposed to film (BioMax
MR; Kodak) for 36 h at room temperature for autoradiographic detection of the
sequence.
Phage ELISA. Individual clones were propagated for 4.5 h in E. coli ER2738
and then they were purified by two precipitations with PEG 8000. Phages (1010)
were added to each well of an Immulon 2HB (Dynex Technologies Inc., Chantilly, Va.) in 0.1 M sodium bicarbonate, pH 8.6, and incubated for 16 h at room
temperature in a humidified chamber. Plates were blocked with PBS containing
10% nonfat dry milk for 3 h at room temperature. Swine sera or MAbs from the
tissue culture supernatant were preadsorbed in PBS containing 10% nonfat dry
milk added with 100 g of E. coli proteins/ml. In addition, 1010 PFU of nonselected phages/ml were added to the antibodies to reduce background caused by
anti-M-13 activity found in animal sera. The plates were washed six times with
PBS–0.05% Tween 20 (PBST), and the peroxidase-conjugated secondary antibody (1:500) was added for 30 min at 37°C. The plates were washed six times, and
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TABLE 1. Sequences of the synthetic peptides useda
Peptide

Sequence

S1.......................................................VLVNANNSSSSHFQSIYNC
S2.......................................................SGSGANNSSSSHFQSIYNC
S3.......................................................SGSGANNSSSSGSGSIYNC
S4.......................................................SHITSYPAYFWC
S6.......................................................SGSGANSNSSSHLQLIYNLTLCELC
R4N...................................................ALVNIPISNNLAC
R1N...................................................VLVNSNNSSSSAC
⌬4R1N ..............................................SGSGSNNSSSSAC
P7.......................................................QRAYLELPPWPPC
a
Peptides were produced as described in Materials and Methods. All of them
have a carboxy-terminal cysteine, which allows the coupling to MBS-activated
proteins or ELISA plates.

ABTS (2,2⬘-azinobis[3-ethylbenzthiazolinesulfonic acid]; KPL, Gaithersburg,
Md.) substrate was added for 15 min. The results were read in a spectrophotometer at 405 nm.
The specific reactivity of the serum against the phage-displayed peptide was
calculated as the difference between the reactivity against the tested phage clone
and the reactivity against phages carrying an irrelevant peptide.
Peptide synthesis. Peptides were synthesized by using solid-phase technology
and 9-fluorenylmethoxy carbonyl chemistry at the Protein Core Facility of the
Center for Biotechnology, University of Nebraska. The sequences of the synthetic peptides are shown in Table 1.
Affinity purification of antipeptide antibodies. Two milligrams of each peptide
was coupled to 2 mg of maleimidobenzoyl-N-hydroxysuccimide ester (MBS)activated keyhole limpet hemocyanin (KLH; Pierce, Rockford, Ill.) in accordance with the directions of the manufacturer. The KLH-peptide complexes
were then coupled to 0.3 g of CNBr-activated Sepharose (Amersham Life Sciences, Inc.).
A 2-ml volume of anti-PRRSV-precipitated antibodies was passed through the
column, and specifically bound antibodies were eluted with 100 mM glycine, pH
2.5. The antibodies were concentrated with Centricon 30 (Amicon, Beverly,
Mass.) to a final concentration of 500 ng/l. A 100-l volume of a 20-g/ml
dilution of these antibodies was used in an MBS-activated ELISA plate coated
with different synthetic peptides.
Peptide ELISA. Reacti-Bind maleimide-activated plates (Pierce) were coated
with synthetic peptides in accordance with the directions of the manufacturer.
Briefly, synthetic peptides were diluted in PBS, pH 6.8, to a final concentration
of 50 g/ml and then were used to coat Reacti-Bind maleimide-activated plates
for 5 h at room temperature. Remaining maleimide groups were blocked by a 1-h
incubation with cysteine-HCl (10 g/ml) diluted in PBS, pH 6.8. An extra blocking step was carried out by incubating the plate with PBS containing 10% nonfat
dry milk. Sera, affinity-purified antibodies, or MAbs were added in different
dilutions and incubated for 1 h at room temperature. The plates were washed six
times with PBST, and the peroxidase-conjugated secondary antibody (1:500) was
added for 30 min at 37°C. The plates were washed six times with PBST, and
ABTS (KPL) substrate was added for 15 min. The results were read in a spectrophotometer at 405 nm.
MAb ISU25-C1 inhibition ELISA. Several dilutions of peptide S4 and irrelevant peptide P7 were incubated with MAb ISU25-C1 for 1.5 h at room temperature. The antibody-peptide mixture was then added to ELISA strips coated with
PRRSV-infected or uninfected MARC-145 cells (IDDEX Laboratories, Inc.) for
45 min. The plates were washed six times with PBST, and the peroxidaseconjugated antimouse antibody (1:500) was added for 30 min at 37°C. The plates
were washed six times, and ABTS (KPL) substrate was added for 15 min. The
results were read in a spectrophotometer at 405 nm and were expressed as the
differences between values for infected and noninfected wells.
Anti-S2 affinity-purified antibody inhibition. Several dilutions of peptide S2 or
S3 or irrelevant peptide P7 were incubated with anti-S2 affinity-purified antibodies for 1.5 h at room temperature. Then, the antibody-peptide mixture was added
to Immulon 2HB (Dynex Technologies Inc.) plates coated with 1010 S2-4 phages.
The plates were washed six times with PBST, and the peroxidase-conjugated
antiswine antibody (1:500) was added for 30 min at 37°C. The plates were washed
six times, and ABTS (KPL) substrate was added for 15 min. The results were
read in a spectrophotometer at 405 nm.
Sequencing of ORF 5 of PRRSV isolate KY-35. PRRSV isolate KY-35 was
grown in MARC-145 cells. When cytopathic effect reached 60%, the supernatant
was discarded and cells were resuspended in TRIzol reagent (Gibco, Life Technologies, Grand Island, N.Y.). RNA was isolated and subjected to reverse tran-
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FIG. 1. Deduced amino acid sequences of relevant peptides carried on phage clones obtained in four different selections. Peptides expressed
by phages selected with MAb ISU25-C1 under low- (A) or high-stringency (B) conditions, with swine antibodies possessing high SN titer (C), or
with swine anti-peptide S2 affinity-purified antibodies (D) are shown aligned with PRRSV Iowa strain, PRRSV KY-35, and a consensus sequence
deduced from the ORF 5 products of several North American strains (34). The sequences are given with the standard single-letter amino acid code.
scription. Briefly, 1 g of total RNA was added to a solution containing 50 mM
Tris-HCl, pH 8.3, 50 mM KCl, 50 mM MgCl2, 50 mM dithiothreitol, 50 U of
Moloney murine leukemia virus reverse transcriptase (Fermentas, MBI, Buffalo,
N.Y.), and 20 pmol of primer (GCG GTC ACT ACT ATA TAC GG). This
primer was developed by us, and it anneals with bases 14454 to 14473 of the
PRRSV genome. The whole ORF 5 was amplified with primers CCATTCTGT
TGGCAATTTGA and GCGGTCACTACTATATACGG; annealing was with
nucleotides 13758 to 13777 and 14454 to 14473 of the PRRSV genome, respectively. The amplicon was cycle sequenced in both directions with the same
primers used for amplification.

RESULTS
Affinity selection of PRRSV mimotopes. The epitopes recognized by either swine antibodies with high SN titer or neutralizing MAb ISU25-C1 were selected from a 12-mer phage
display library. The number of recovered phages after the third
panning was at least 100-fold higher than that after the first
panning in all of the selections performed.
In Fig. 1A are shown the sequences of relevant peptides
carried on clones recovered after the third panning of a lowstringency selection performed with MAb ISU25-C1. Three
out of 15 clones with an SH motif were found. In another
selection with MAb ISU25-C1 under high-stringency conditions, all phages in the third panning carried an identical peptide with a SHI motif (Fig. 1B). The SH(I/L) motif is found in

residues 37 to 39 of GP5 of the PRRSV KY-35 isolate, which
was the isolate used to immunize the mice for the production
of MAb ISU25-C1.
Anti-PRRSV affinity-purified antibodies with high SN titer
were used to select phages from the library, and several clones
carrying amino-terminal motif ALVN were recovered (Fig.
1C). This is a consensus motif found in residues 27 to 30 of
PRRSV GP5 (31). Another clone selected with the swine antibodies with high SN titer (clone 18) expressed a peptide with
a YNL motif, which is also a consensus motif found in amino
acids 43 to 45 of PRRSV GP5. Finally, clone 14 carried an HF
motif, which is found in residues 38 to 39 of GP5 of a PRRSV
IA 97-7895 isolate, which was the primary PRRSV strain used
to immunize the pigs.
Anti-peptide S2 affinity-purified antibodies were used to select phages from the library, and 4 out of 12 selected clones
corresponded to a single clone (clone S2-4), containing an
HLXLIYN motif. This motif is also found between amino
acids 38 and 44 of the consensus sequence of PRRSV GP5
(Fig. 1). Another clone selected with these antibodies (clone
S2-12) contained an HFQ motif located between residues 38
and 40 of GP5 of the PRRSV Iowa strain.
Two independent epitopes are located in the ectodomain of
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TABLE 2. Reactivity of swine sera and MAbs to selected cloned phages
Phagotope

Clone 01 (epitope A) ALVNIPISNNLA
Clone 5.1 (epitope B) SHITSYHPAYFW
Clone S2-4 (epitope B) YKNTHLDLIYNA

Reactivitya with primary antibody:
ISU25-C1

ISU19-A1

NS 6b

NNS 5c

Swine negative serum

0.045 (⫾ 0.008)
0.500 (⫾ 0.003)
0.008 (⫾ 0.001)

0.087 (⫾ 0.006)
0.067 (⫾ 0.005)
0.039 (⫾ 0.014)

0.373 (⫾ 0.016)
0.027 (⫾ 0.035)
0.371 (⫾ 0.05)

0.855 (⫾ 0.040)
0.031 (⫾ 0.018)
0.021 (⫾ 0.020)

⫺0.022 (⫾ 0.002)
0.037 (⫾ 0.031)
0.045 (⫾ 0.020)

a

Results are expressed as corrected OD at 405 nm (OD for selected phage ⫺ OD for unselected phage library) (⫾ standard deviation).
NS 6, NS from pig 6 with a neutralizing titer ⬎64 and an ELISA S/P ratio of 1.053.
c
NNS 5, NNS from pig 5 with a neutralizing titer ⬍4 and an ELISA S/P ratio of 0.652.
b

PRRSV GP5. Several phage clones were tested in a phage
ELISA format. Table 2 shows that the peptide displayed by
phage clone 5.1, which carries an SH(I/L) motif corresponding
to a putative epitope that we named epitope B, was strongly
recognized by MAb ISU25-C1. However, this peptide was not
recognized by either swine anti-PRRSV NS or NNS. Conversely, phage clone 01, expressing a peptide with an ALVN
amino-terminal motif corresponding to a putative recognition
site that we named epitope A, was strongly recognized by
anti-PRRSV NS and NNS but was not recognized by MAb
ISU25-C1.
Phage clones 10.1, 29, 10.3, and S2-12 were tested in the
phage ELISA, and all of them were negative with MAb
ISU25-C1 and swine NS and NNS (data not shown).
Based on the previous results, several peptides comprising
one or both of these motifs in different amino acid contexts
were chemically synthesized and tested using either swine antiPRRSV sera or MAb ISU25-C1 (Table 3). MAb ISU25-C1
recognized peptide S4, which was deduced from the sequence
of the peptide carried on phage clone 5.1. The specificity of
MAb ISU25-C1 for peptide S4 was confirmed by an experiment involving inhibition of binding in an ELISA. Figure 2
shows that, at a concentration of 333 M, peptide S4 inhibited
60% of the binding of MAb ISU25-C1 to PRRSV.
Several different swine NS recognized peptides R4N and
R1N. Peptide R4N corresponds to the sequence of the peptide
expressed by phage clone 01, and peptide R1N represents
amino acids 27 to 38 of the GP5 of the PRRSV IA 97-7895
isolate. Both peptides have an (A/V)LVN motif, which corresponds to amino acids 27 to 30 of GP5 of PRRSV. The signal
was considerably reduced when these residues (27 to 30;
VLVN in peptide R1N) were changed to irrelevant motif
SGSG in peptide ⌬4R1N (Table 3).
Peptide S1 represents residues 27 to 43 of GP5 of IA 977895 and contains motifs VLVN and SHF. This peptide was
strongly recognized by swine NS. Peptide S2, which is identical
to peptide S1 except that motif VLVN was replaced with an
SGSG motif, was still recognized by swine NS, although with a
considerable reduction in the ELISA signal. In addition, the
signal was further reduced when motifs VLVN and SHF were
replaced by amino acids SGSG and GSG, respectively (peptide
S3), indicating that these motifs are key components of their
respective epitopes.
Based on the previous results, anti-epitope A and antiepitope B antibodies were affinity purified from a pool of
precipitated antibodies with an SN titer of 512 by using KLHconjugated peptides R4N and R1N and peptide S2, respectively. The peptide-KLH complexes were coupled to CNBractivated Sepharose as the ligand, and antibodies eluted from

these columns were used to detect synthetic peptides in ELISA
(Table 4). Anti-peptide R4N and R1N affinity-purified antibodies recognized peptides R4N, R1N, and S1. All of these
peptides contain an (A/V)LVN motif. However, these antibodies did not recognize peptides S2 or ⌬4R1N in which N-terminal residues VLVN were changed to SGSG. Conversely, S2
affinity-purified antibodies recognized peptides S1 and S2, containing the SHF motif, but did not recognize peptides R4N,
R1N, and S3, which lack this motif. Since peptide S3 only
differs from peptide S2 in that in the former the SHF motif was
replaced by GSG, these data confirm the importance of at least
one of these three amino acids for antibody binding.
The signal obtained by ELISA by using peptide S1 as the
antigen and a mixture of affinity-purified anti-R4N and -R1N
and anti-S2 antibodies as primary antibodies is higher than the
signals obtained by using these antibodies separately (Table 4).
This indicates that the binding of antibodies to one of the
epitopes does not interfere with the binding of antibodies to
the other epitope.
Altogether, these results indicate that in swine PRRSV NS
there are antibodies directed to two putative epitopes located
in the ectodomain of GP5. One of these epitopes (epitope A)
comprises the stretch of amino acids including residues (A/
V27)L28V29N30 of GP5. The other epitope (epitope B) comprises the stretch of amino acids including residues S37H38(F/
L)39. The S37H38(L/I)39 motif recognized by neutralizing MAb
ISU25-C1 is located in the epitope B area.
Further characterization of epitope B. To further characterize epitope B, anti-peptide S2 affinity-purified antibodies were
used to screen the phage display library. Four out of 12 selected phage clones carried a peptide with a YKNTHLDLI
YNA sequence (Fig. 1D). Motif HXXXIYN, found in this
phage, is also found in all of the five PRRSV isolates used to
immunize the pigs. Moreover, motif HLQLIYN is present
between residues 38 and 44 of the PRRSV consensus sequence
encoded by ORF 5 (30). In addition, another phage clone
(clone S2-12) selected with these antibodies expressed an HFQ
motif, which is also located at amino acids 38 to 40 of the
PRRSV Iowa strain. This may indicate that some of the antipeptide S2 affinity-purified antibodies could also recognize the
two amino acids located downstream from H39.
Phage clone S2-4 was assayed in a phage ELISA with MAb
ISU25-C1 and swine anti-PRRSV sera (Table 2). While swine
NS recognized this clone, swine NNS did not recognize it. In
addition, MAb ISU25-C1 did not recognize this phage clone.
The deduced sequences of the peptides expressed by phages
selected with MAb ISU25-C1, swine antibodies with high SN
titer, and anti-peptide S2 affinity-purified swine antibodies
(Fig. 1) suggested that epitope B is composed of two stretches

⫺0.054 (⫾ 0.399)

1.811 (⫾ 0.014)
⫺0.04 (⫾ 0.031)
⫺0.001 (⫾ 0.006)
⫺0.031 (⫾ 0.002)

0.017 (⫾ 0.009)

0.037 (⫾ 0.002)
0.041 (⫾ 0.006)
0.094 (⫾ 0.058)
⫺0.007 (⫾ 0.008)

Results are expressed as corrected OD at 405 nm (OD for selected phage ⫺ OD for unselected phage library) (⫾ standard deviation).
SN titer was determined against the PRRSV Iowa strain. ELISA S/P ratio was determined as described in Materials and Methods. Sera 3, 5, 6, and 8 are from PRRSV-hyperimmunized pigs, serum 19 is a negative
control (see Materials and Methods), ISU25-C1 and ISU19-A1 are anti-PRRSV neutralizing and nonneutralizing MAbs, respectively.
b

a

⫺0.014 (⫾ 0.014)
⫺0.023 (⫾ 0.000)
0.020 (⫾ 0.001)
0.013 (⫾ 0.005)

S1 (epitopes A and B) VLVNANNSSSSHFQSIYNC
1.780 (⫾ 0.045)
0.503 (⫾ 0.011)
0.626 (⫾ 0.006) 0.720 (⫾ 0.013)
0.099 (⫾ 0.008)
S2 (epitope A removed, epitope B present) SGSGA
0.152 (⫾ 0.033)
0.189 (⫾ 0.019)
0.284 (⫾ 0.002) 0.051 (⫾ 0.001)
0.036 (⫾ 0.006)
NNSSSSHFQSIYNC
S3 (epitopes A and B removed) SGSGANNSSSSGS
0.005 (⫾ 0.021)
0.092 (⫾ 0.002)
0.161 (⫾ 0.014) 0.019 (⫾ 0.014)
0.020 (⫾ 0.011)
GSIYNC
S4 (mimotope B) SHITSYHPAYFWC
⫺0.004 (⫾ 0.014) ⫺0.185 (⫾ 0.001) ⫺0.161 (⫾ 0.001) ⫺0.09 (⫾ 0.003) ⫺0.100 (⫾ 0.001)
R4N (mimotope A) ALVNIPISNNLAC
1.784 (⫾ 0.022)
0.599 (⫾ 0.004)
1.061 (⫾ 0.003) 1.205 (⫾ 0.018)
0.211 (⫾ 0.002)
R1N (epitope A) VLVNSNNSSSSAC
1.679 (⫾ 0.085)
0.653 (⫾ 0.005)
0.753 (⫾ 0.016) 0.716 (⫾ 0.011)
0.177 (⫾ 0.001)
⌬4R1N (epitope A removed) SGSGSNNSSSSAC
⫺0.010 (⫾ 0.021)
0.123 (⫾ 0.016)
0.174 (⫾ 0.001) 0.010 (⫾ 0.006) ⫺0.033 (⫾ 0.018)

ISU25-C1 (8, 0.190)

J. VIROL.

ISU19-A1 (⬍2, 0.441)
19 (⬍4, ⬍0.4)
5 (64, 1.677)
3 (64, 1.835)

Peptide

6 (64, 1.053)

8 (128, 1.712)

Reactivitya with serum or primary antibody (SN titer, ELISA S/P ratio)b:
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TABLE 3. Reactivity of MAb ISU25-C1 and swine anti-PRRSV hyperimmune sera to synthetic peptides bound to MBS-coated ELISA plates
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FIG. 2. Inhibition by synthetic peptides of the binding of MAb
ISU25-C1 (solid lines) and MAb ISU19-A1 (dotted lines) to PRRSV
in ELISA. Serial fivefold dilutions of synthetic peptide S4 were used
(■). Unrelated peptide P7 was used with MAb ISU25-C1 as a negative
control (F). Results are percentages of the anti-PRRSV-specific signal
obtained with each MAb in wells to which no peptides were added.
Values are averages of four readings.

of amino acids, located among positions S37H38(L/F)39 and
among positions I42Y43N44L45 of PRRSV GP5. To confirm
these results, inhibition experiments were performed with peptides S2 and S3 (Fig. 3). Although both peptides inhibited the
binding of anti-peptide S2 affinity-purified antibodies to clone
S2-4, peptide S2 inhibited it to a greater extent than peptide
S3. This stresses the importance of motif SHF in the composition of epitope B.
To determine if substitutions in the amino acids surrounding
the core of epitope B could affect the recognition of this
epitope, the binding of anti-peptide S2 affinity-purified antibodies was assessed with peptides S2 and S6. The latter corresponds to residues 27 to 51 of the GP5 of the PRRSV KY-35
isolate, except that residues 27 to 30 (epitope A) were replaced
by irrelevant motif SGSG. Anti-peptide S2 affinity-purified antibodies recognized to a similar extent peptides S2 (OD, 0.336)
and S6 (OD, 0.369), confirming that residues H38, Q40, I42, Y43,
and N44 constitute the core of epitope B.
Difference in the kinetics of appearance of antibodies induced by epitopes A and B. A characteristic feature of PRRSV
infection is that anti-PRRSV NAs appear late after infection.
Moreover, natural infection or vaccination with PRRSV induces low levels of NAs. Thus, to obtain SN titers over 16, it
was necessary to subject the pigs to the complex hyperimmunization scheme described in Materials and Methods. In an
attempt to determine if there was a correlation between time
p.i. and epitope recognition by serum antibodies, sera from
several pigs obtained at two different times of the hyperimmunization protocol were evaluated (Table 5).
Sera obtained shortly after the beginning of the immunization, which were positive for PRRSV by ELISA but which had
low or undetectable SN titers, reacted very strongly with epitope A (phage clone 01) and very weakly with epitope B
(phage clone S2-4). These results confirm that epitope A is
immunodominant and not associated with viral neutralization.
Sera from the same animals were tested after repeated immunizations, when SN titers had reached 32 to 128. Table 5
shows that, at this time, the response against epitope B is
considerably increased. These results, together with our finding that epitope B is the target for neutralizing MAb ISU25-
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TABLE 4. Reactivity of antipeptide affinity-purified antibodies to synthetic peptides bound to MBS-coated ELISA plates
Reactivitya for:

Peptide

S1 (epitopes A and B) VLVNANNSSS
SHFQSIYNC
S2 (epitope A removed, epitope B
present) SGSGANNSSSSHFQSIYNC
S3 (epitopes A and B removed)
SGSGANNSSSSGSGSIYNC
S4 (mimotope B) SHITSYHPAYFWC
R4N (mimotope A) ALVNIPISNNLAC
R1N (epitope A) VLVNSNNSSSSAC
⌬4R1N (epitope A removed) SGSGSN
NSSSSAC
a
b
c

Eluted S4 column

Eluted P7b column

0.436 (⫾ 0.006)

0.007 (⫾ 0.006)

⫺0.008 (⫾ 0.003)

0.336 (⫾ 0.005)

0.351 (⫾ 0.025)

0.008 (⫾ 0.000)

0.007 (⫾ 0.024)

0.001 (⫾ 0.002)

0.003 (⫾ 0.004)

0.000 (⫾ 0.001)

0.002 (⫾ 0.001)

⫺0.009 (⫾ 0.005)

⫺0.007 (⫾ 0.001)
0.540 (⫾ 0.027)
0.410 (⫾ 0.024)
0.005 (⫾ 0.008)

0.010 (⫾ 0.021)
0.002 (⫾ 0.002)
0.000 (⫾ 0.005)
0.001 (⫾ 0.003)

NDc
ND
ND
ND

⫺0.005 (⫾ 0.005)
0.010 (⫾ 0.006)
0.009 (⫾ 0.001)
0.004 (⫾ 0.001)

⫺0.010 (⫾ 0.003)
0.015 (⫾ 0.007)
0.005 (⫾ 0.019)
0.004 (⫾ 0.009)

Eluted S2 column

Eluted S2 ⫹ eluted R1N

0.164 (⫾ 0.012)

0.269 (⫾ 0.007)

⫺0.004 (⫾ 0.004)

Eluted R4N-R1N column

Results are expressed as corrected OD at 405 nm (OD for tested peptide ⫺ OD for irrelevant peptide P7) (⫾ standard deviation).
Irrelevant peptide P7 (QRAYLELPPWPP).
ND, not done.

C1, demonstrate that this epitope is associated with PRRSV
neutralization.
DISCUSSION
In this report, we identified and characterized two epitopes
located in the ectodomain corresponding to the amino-terminal area of GP5 of PRRSV. The use of swine polyclonal antibodies in conjunction with murine MAbs allowed us to thoroughly characterize this antigenic region of GP5.
Residues 27A/(V)L28V29N30 of PRRSV GP5 are the main
antibody recognition site for epitope A. The replacement of
these four amino acids with an irrelevant SGSG motif considerably reduced the recognition of this epitope, which is present
in several different synthetic peptides (Tables 3 and 4). Epitope
A is strongly recognized by swine sera obtained early after
infection, when neutralizing activity cannot be detected in
these sera (Table 5), indicating that this epitope is not involved
in viral neutralization. Nevertheless, epitope A is highly immunodominant all throughout the immune response. This observation could explain why, although a subtraction of nonneutralizing epitopes from the 12-mer phage display library with
NNS was performed, several clones displaying peptides resembling epitope A were still selected with NS obtained from
animals during late stages of infection (Fig. 1).
Epitope B is located in a region of GP5 that comprises
residues 37 to 45. This region is recognized both by neutralizing MAb ISU25-C1 and swine sera with high neutralizing titers
but not by swine NNS. A comparison of the sequences of
several PRRSV isolates demonstrates that the area where
epitope B is located is conserved. Moreover, anti-peptide S2
affinity-purified antibodies recognized to a similar extent the
epitope variants present in PRRSV IA 97-7895 (HFQSIYN)
and PRRSV KY-35 (HLQIYN), two highly divergent North
American isolates. In addition, these antibodies recognized the
mimotope carried by phage clone S2-4 (HLDLIYN). These
observations could explain the broad neutralizing activity of
MAb ISU25-C1 (40). Additionally, these results demonstrate
that residues H38 and I43Y44N45 are the main recognition site
in epitope B. Nevertheless, it seems that residues 39 to 41
contribute to the binding to antibodies, since the peptide carried on phage clone S2-4 contains leucines 40 and 42, which are
also present in PRRSV isolate KY-35. This finding regarding

the presence of a sequential neutralizing epitope is in agreement with previous reports indicating the ability of MAb
ISU25-C1 to recognize the denatured GP5 (40). Furthermore,
the presence of sequential neutralizing epitopes in GP5 of
PRRSV has also been described by others (28).
The product of ORF 5 of lactate dehydrogenase-elevating
virus (LDV), a murine arterivirus, has more than 60% similarity at the amino acid level with the GP5 of PRRSV (Fig. 4). A
neutralizing epitope located between residues 37 and 60 of the
LDV ORF 5 product was described (17). The key residues in
this epitope were identified. Interestingly, they correspond to
the residues identified by us as part of the main recognition site
for NAs in epitope B. For example, threonine39 of the ORF 5
product of LDV, which corresponds to histidine38 in PRRSV
GP5, seems to be key to recognition by anti-LDV neutralizing
MAbs 159-12 and 159-18, as it was the only residue mutated
(T3A) in an LDV neutralization escape mutant. Moreover,
neutralizing MAb 159-19 (which reacts with the same epitope
recognized by Mabs 159-12 and 159-18) recognized peptides
with substitutions at I43 or Y44 to a lesser extent than the
original peptide, indicating that both residues contribute to
this epitope. It seems that residue H38 in PRRSV GP5 is also
relevant for the binding of swine antibodies to epitope B, since
the substitution of G for H completely eliminated the recog-

FIG. 3. Inhibition by synthetic peptides of the binding of anti-peptide S2 affinity-purified antibodies to phage clone S2-4. Serial fivefold
dilutions of synthetic peptides S2 (■) and S3 (⫻) and irrelevant peptide P7 (F) were used. Results are percentages of the signal obtained
with anti-peptide S2 affinity-purified antibodies in wells to which no
peptides were added. Values are the averages of four readings.

A (0.652, 0)
B (1.993, 128)
A (1.382, 4)
B (2.030, 512)
A (1.078, 0)
B (1.998, 64)
A (1.266, 4)
B (1.755, 32)
A (1.432, 0)

Recognition is expressed as corrected OD at 405 nm (OD for phage clone ⫺ OD for unselected phage library) (⫾ standard deviation).
Times A and B correspond to early (20 days p.i.) and advanced (7 months p.i.) stages of the hyperimmunization protocol, respectively. Values in parentheses are ELISA S/P ratios, determined as indicated in Materials
and Methods, followed by SN titers.
b

a

B (1.712, 128)
B (1.29, 64)

A (0.946, 0)

8
5
4
3
2
1
Epitope

Recognitiona at indicated timeb by sample from pig:

J. VIROL.
A (clone S2-4) 0.019 (⫾ 0.020) 0.072 (⫾ 0.016) 0.033 (⫾ 0.004) 0.170 (⫾ 0.011) 0.014 (⫾ 0.011) 0.155 (⫾ 0.005) 0.000 (⫾ 0.027) 0.493 (⫾ 0.012) 0.021 (⫾ 0.004) 0.062 (⫾ 0.001) 0.044 (⫾ 0.015) 0.249 (⫾ 0.004)
B (clone 01)
0.738 (⫾ 0.018) 0.289 (⫾ 0.019) 0.782 (⫾ 0.039) 0.237 (⫾ 0.019) 0.704 (⫾ 0.069) 0.594 (⫾ 0.037) 0.689 (⫾ 0.019) 0.755 (⫾ 0.017) 0.855 (⫾ 0.04) 0.431 (⫾ 0.019) 0.828 (⫾ 0.008) 0.231 (⫾ 0.005)
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nition (Tables 3 and 4 and Fig. 3). The use of anti-peptide S2
affinity-purified antibodies confirmed this assertion, since the
use of these antibodies to select epitopes from the phage library resulted in a significant enrichment of phage clone S2-4.
This phage clone carries a peptide with an HLDLIYN motif
(Fig. 1). Thus, epitope B seems to be the counterpart of the
LDV neutralizing epitope. The high degree of conservation
among PRRSV isolates in the area where epitope B is located
suggests that this region has an important functional or structural role for these viruses. Thus, the number of mutations in
this area that do not adversely affect viability may be limited.
The titer of anti-epitope B antibodies in sera is low at the
beginning of the hyperimmunization protocol (Table 5, time
point A). At this time, NAs are not present in serum (SN titer,
⬍4; ELISA S/P ratio, ⬎0.652). Later, when the SN titer increases to ⬎32, antibodies against epitope B dramatically rise.
A similar scenario in humans infected with human immunodeficiency virus (HIV) was described. MAb I5e, recognizing a
broadly neutralizing epitope on HIV gp120, was characterized
(14). Sera obtained from patients less than 6 months after
infection did not compete with this MAb for binding HIV in
ELISA. However, sera obtained from patients six or more
months after infection competed with neutralizing MAb I5e
for the epitope in HIV. The recognition of this neutralizing
epitope was associated with the development of a neutralizing
activity in the sera (14). It seems that PRRSV also delays the
induction of NAs, at least to epitope B, as described for the
epitope of HIV recognized by MAb I5e.
Only a fraction of the repertoire of B-cell epitopes presented
by a protein antigen are functionally capable of eliciting antibodies. It has been proposed that the chemical composition of
a given epitope could influence at least one of the parameters
that defines its immunodominance (21). Thus, it is possible
that epitope A has evolved to behave as a decoy epitope, luring
the immune response away from more-protective targets
present in GP5 such as neutralizing epitope B. Indeed, epitope
A exhibits some features expected of a decoy epitope (10),
such as its high immunogenicity expressed rapidly after infection and its hypervariability (30). In other viral infections,
decoy epitopes have been shown to act by suppressing the
recognition of neutralizing epitopes. For example, the dampening of an immunodominant epitope on gp120 of HIV allowed the refocusing of the NA response toward a previously
silent, qualitatively different, second-order neutralizing epitope (10). In addition, neutralizing epitope ERDRD on gp41
of HIV type 1 was demonstrated to be immunogenic in rabbits.
However, this response is completely eliminated when epitope
ERDRD is presented on a peptide juxtaposed to immunodominant epitope IEEE, located two amino acids away in the
native sequence of gp41 (7). Thus, decoy epitope IEEE decreases the antibody response to the ERDRD neutralizing
epitope. Epitope A of PRRSV, which is located seven amino
acids apart from neutralizing epitope B, could be acting similarly to the ERDRD epitope of HIV.
Although MAb ISU25-C1 did not bind to any of the peptides
representing fractions of the PRRSV IA 97-7095 ectodomain
(Table 3), the consensus motif which it recognizes (SH[L/I])
aligns with that of GP5 of PRRSV Iowa strain in this region. In
contrast, swine HI sera did not react with the mimotope recognized by MAb ISU25-C1 but instead reacted with the native
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FIG. 4. Comparison of the predicted amino acid sequences of GP5 of PRRSV and LDV. The predicted amino acid sequences of PRRSV
isolate IA 79-7895 GP5 (1) and the product of LDV ORF 5 (9) are compared. Hyphens, identical amino acids; dots, gaps; single underlining
(PRRSV), key residues in epitope A; double underlining (PRRSV and LDV), epitope B area; arrow, the only residue mutated in GP5 of an LDV
neutralization escape mutant (20).

sequence deduced from PRRSV GP5. Differences in recognition by mouse and pig antibodies have been reported before
(25). It is not surprising since swine antibodies are limited to
the usage of the products of only one family of variable heavy
genes which are homologous to the 7183 VH family of mouse
antibodies (4) whereas MAb ISU25-C1 uses the most distant
J558 VH family of antibodies (unpublished results), confirming
that epitopes can only be defined in terms of their complementary paratopes (36). Alternatively, the nonrecognition of synthetic peptides by MAb ISU25-C1 could be a consequence of
the absence of glycosylation. The epitope B region is highly
glycosylated, and MAb ISU25-C1 does not recognize an E.
coli-expressed GP5 (R. Bastos, personal communication).
Thus, besides the amino acids described here, sugars could be
involved in this epitope.
Despite being separated by only seven amino acids, both
antigenic regions identified here are independent epitopes.
Both epitopes can be recognized simultaneously by different
populations of antibodies in serum without any interference
between them (Table 4). Moreover, the increase in the titer of
antibodies against epitope B correlates with a decrease in the
level of antibodies against epitope A (Table 5).
In summary, herein we demonstrate that two epitopes exist
in the ectodomain of GP5 of PRRSV. Epitope A is immunodominant and induces a rapid rise of antibodies without neutralizing activity. NAs targeting epitope B appear later in the
immune response, when PRRSV is being cleared from the
animal. Epitope B is conserved among isolates, making it a
suitable target for a more efficient vaccine for PRRSV.
Recent results from different laboratories have stressed the
importance of NAs in protection against infection. The findings described herein could help in the understanding of
PRRSV pathogenesis and the development of a protective
immune response against it.
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ERRATUM
Identification of Neutralizing and Nonneutralizing Epitopes in the Porcine
Reproductive and Respiratory Syndrome Virus GP5 Ectodomain
M. Ostrowski, J. A. Galeota, A. M. Jar, K. B. Platt, F. A. Osorio, and O. J. Lopez
Wolf Biotech and University of Nebraska, Lincoln, Nebraska; University of Buenos Aires,
Buenos Aires, Argentina; and Iowa State University, Ames, Iowa
Volume 76, no. 9, p. 4241–4250, 2002. Page 4248, Table 5, “Epitope” column: “A (clone S2-4)” should read “B (clone S2-4)”
and “B (clone 01)” should read “A (clone 01).”
Page 4248, column 2, line 7 from bottom: “ERDRD” should read “IEEE.”
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